Terada, Mitsuo
Kondo, Naoto
Wanifuchi-Endo, Yumi
Fujita, Takashi
Asano, Tomoko
Hisada, Tomoka
Uemoto, Yasuaki
Akiko Kato,
Yamanaka, Natsumi
Sugiura, Hiroshi
Mita, Keiko
Wada, Asaka
Takahashi, Eriko
Saito, Kanako
Yoshioka, Ryo
Toyama, Tatsuya http://orcid.org/0000-0003-4713-7795
Article History
Received: 23 May 2022
Accepted: 20 July 2022
First Online: 8 August 2022
Declarations
:
: The authors declare that they have no conflict of interest.
: The first protocol for this study (protocol no. 60–21-0019) was approved by the institutional review board of Nagoya City University Graduate School of Medical Sciences in June 2021. This study conformed to the guidelines of the Declaration of Helsinki. SARS-CoV-2 vaccinations started in Japan in February 2021 with Pfizer-BioNTech BNT162b2 mRNA vaccine (BNT162b2 vaccine). Three months later, mRNA-1273 Moderna COVID-19 vaccine (mRNA-1273 vaccine) was approved in Japan in March 2021. The interventional amendment to the protocol and subsequent enrollment for patients with mRNA-1273 was activated in July 2021.
: At enrollment, written informed consent was collected from all participants.
: All participants signed informed consent regarding publishing their data.
Free to read: This content has been made available to all.